Efficacy of Butylphthalide Combined with Edaravone Dexborneol in the Treatment of Patients with Large Cerebral Infarction and its Effect on Serum Related Indicators
CHEN Xiaoru, LIN Chong
Department of Neurology, Affiliated Hospital of Xi'an Medical College, Xi'an Shaanxi 710309
Abstract 【Objective】To investigate the efficacy of butylphthalide combined with edaravone dexborneol in the treatment of patients with large cerebral infarction (LCI) and its effect on serum neuron-specific enolase (NSE), astrocyte-derived protein (S100B), and glial fibrillary acidic protein (GFAP).【Methods】 A total of 120 patients with LCI were randomly divided into an observation group (treated with butylphthalide combined with edaravone dexborneol) and a control group (treated with edaravone dexborneol alone). The clinical efficacy, NIHSS scores and ADL scores before and after treatment were compared between the two groups. Serum levels of NSE, S100B, and GFAP, as well as whole blood viscosity and plasma viscosity before and after treatment, were measured and compared between the twomgroups. The incidence of adverse reactions in the two groups was also compared.【Results】 The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the NIHSS scores of both groups were significantly lower, and the ADL scores were significantly higher than before treatment (P<0.05). The NIHSS score in the observation group was lower than that in the control group, and the ADL score in the observation group was higher than that in the control group (P<0.05). Post-treatment serum levels of NSE, S100B, and GFAP, as well as whole blood viscosity and plasma viscosity, were significantly lower if compared to pre-treatment levels. And all these measurement levels in the observation group were lower than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 The combination of butylphthalide and edaravone dexborneol is effective in treating LCI, improving neurological function, and reducing levels of NSE, S100B, and GFAP, as well as blood viscosity. This treatment enhances the quality of life and has good safety.
CHEN Xiaoru,LIN Chong. Efficacy of Butylphthalide Combined with Edaravone Dexborneol in the Treatment of Patients with Large Cerebral Infarction and its Effect on Serum Related Indicators[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1395-1397.
2024, Vol. 41 
